A repeatable matrix process
An iPSC-derived, collagen-rich extracellular matrix process aimed at repeatable matrix production.
Research programAllograft, synthetic and marrow-collection products for fusion, from a team that has spent twenty years in the operating room with surgeons.
Cortical fiber, DBM putty and cancellous bone in moldable, flowable and strip forms.

Bioactive glass, bioceramic and collagen matrices chosen on their own merit, not as a fallback.

A focused system for recovering bone marrow aspirate at the point of care.

Bioactive glass, finally in a form that behaves in the hand. PURactiveOrb packs 45S5 bioactive glass into engineered spheres of two sizes, about 80% glass by weight, in a moldable, non-hardening phospholipid putty. Shape it, place it, and let the carrier get out of the way.


The allograft surgeons reach for by feel. PURbonedough is 100% demineralized cortical bone in a dough that holds together, holds its shape and packs exactly where you put it, with every lot verified for osteoinductive potential before it ships.
Accreditation and sterility assurance are the entry ticket in this market. What separates a graft is the judgment behind it.
Donor source quality and selection judgment built case by case, not read from a spec sheet.
Allograft DBM lots are tested for osteoinductive potential before release, not sampled.
Processing designed to deliver a sterile graft without degrading the activity surgeons are relying on.
Multiple qualified tissue sources so supply does not dictate the surgeon's choice of graft.

PURactiveOrb is available with a minimally invasive delivery option: a trigger-fed instrument and cannula that place putty through a small access corridor.
PUR Biologics is a commercial-stage orthobiologics company based in Irvine, California. For thirteen years we have brought allograft, synthetic graft and marrow-collection products to spine and orthopedic surgeons through a focused portfolio and direct relationships with the people who use it.
We work with surgeons, hospitals and surgery centers, and distribution partners across the United States.

Why it matters
A 510(k)-cleared HA/TCP sphere platform in a mesh format for posterolateral spine graft extension, moving through manufacturing transfer.
Granted patents and applications spanning extracellular matrix manufacturing and regenerative cell-activation technologies.
Three research directions exploring how matrices and defined chemistry can inform future biologic technologies.
Product literature, current instructions for use, ordering, or a conversation about distribution. Our team answers directly.
Twelve products across three families. Each one is here because it does a specific job in the fusion better than the alternative.
The bioactive glass putty surgeons can shape. 45S5 glass in engineered spheres, about 80% glass by weight, in a resorbable phospholipid carrier: moldable, non-hardening, resists irrigation, and ready through a 9 mm cannula.

45S5 bioactive glass is among the most studied synthetic graft materials in orthopedics. Conventional putties use it as crushed, irregular particles. PURactiveOrb uses spheres: two engineered diameters, 90–180 µm and 355–500 µm, blended in a fixed ratio so the particles pack densely and present a consistent surface to surrounding bone.
The result is a putty that is about 80% bioactive glass by weight, roughly 1.5 grams of glass in every cc, bound by a natural phospholipid carrier that gives it its feel. After placement the carrier is resorbed and the glass remains in direct contact with host bone.
In a preclinical rabbit defect model, new bone formed directly on the sphere surfaces and in the spaces between them, with bone present throughout the implant area at six weeks.1
Supplied in an open-bore syringe sealed within two foil pouches, in 2.5, 5 and 10 cc volumes. No hydration step.
1 Preclinical animal study, data on file. Results in animal models do not necessarily predict clinical performance in humans.

A trigger-fed instrument and cannula place PURactiveOrb through a minimally invasive corridor in controlled increments.
PURactiveOrb Putty is indicated for bony voids or gaps that are not intrinsic to the stability of the bony structure. It is indicated as a bone void filler in the extremities and pelvis, and as a bone graft extender in the posterolateral spine.
For posterolateral fusion, PURactiveOrb Putty must be mixed with autograft in a 1:1 ratio.
This summary does not replace the complete instructions for use, including contraindications, warnings, precautions and directions.
Do not add fluid directly to the putty, including blood or saline. This may negatively affect handling and cohesiveness. Refer to the current IFU for preparation and use.
The product does not possess sufficient mechanical strength to solely support defect reduction. Appropriate stabilization is required. The product is for single-patient, single use only.
Distinctive materials, protected technologies and a research program built around regenerative medicine.
A synthetic graft platform of porous HA/TCP spheres contained in a mesh format, developed for posterolateral spine graft extension. The platform is 510(k)-cleared; manufacturing transfer and shelf-life work are the next milestones on the path to commercial release.
This platform is distinct from PURactiveOrb Putty, our bioactive glass product.
PUR's intellectual-property portfolio spans extracellular matrix manufacturing and regenerative cell-activation technologies, with patent work extending into bone and cartilage programs. These technologies form the foundation for a research pipeline that reaches beyond today's commercial catalog.
An iPSC-derived, collagen-rich extracellular matrix process aimed at repeatable matrix production.
Research programPatent work spanning cartilage regeneration, alongside PUR's broader matrix and bone-focused programs.
Patent & research focusA defined molecular composition intended to activate bone-marrow-derived immune cells, with bone regeneration as an initial application.
Research programResearch programs describe development objectives, not established clinical outcomes or commercially available treatments. The sphere platform's clearance does not apply to the ECM, cartilage or immune-activation programs.